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Abstract
Background—Quality of oncologic outcomes is of paramount importance in the care of patients 
with non-small cell lung cancer (NSCLC). We sought to evaluate the relationship of hospital 
volume for lobectomy on cancer-specific survival in NSCLC patients treated in California, as well 
as the influence of Committee on Cancer (CoC) accreditation.
Methods—The California Cancer Registry was queried from 2004–2011 for cases of Stage I 
NSCLC and 8,345 patients were identified. Statistical analysis was used to determine prognostic 
factors for cancer-specific survival.
Results—7,587 patients were treated surgically. CoC accreditation was not significant for 
cancer-specific survival, but treatment in high volume centers was associated with longer survival 
when compared to low and medium volume centers (HR 1.77, 1.474–2.141 and HR 1.23, 1.058–
1.438).
Conclusions—These data suggest that surgical treatment in high volume hospitals is associated 
with longer cancer-specific survival for early-stage NSCLC, but that CoC accreditation is not.
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Lobectomy with mediastinal lymphadenectomy is the standard of care for the treatment of 
early-stage non-small cell lung cancer (NSCLC). Although previous studies show a 
relationship between hospital procedural volume and perioperative outcomes, we sought to 
evaluate the relationship of hospital volume on cancer-specific survival in early-stage 
NSCLC patients treated in California, as well as the influence of facility American College 
of Surgeons Commission on Cancer (CoC) accreditation on long-term outcomes.
Background
In the modern era, where perioperative outcomes are scrutinized and publicized no one 
single measure of quality exists. Many studies have evaluated the relationship between 
hospital procedural volume and perioperative outcomes and have attempted to use hospital 
volume as a surrogate for quality [1–9]. In the United States and England, there is a trend of 
improved perioperative complications and mortality in high volume centers [1–6]. European 
studies, in contrast, find that surgeon volume rather than hospital volume contributes to 
perioperative morbidity and that hospital volume should not be considered a substitute for 
quality outcomes [7–9]. Cancer-specific survival is rarely considered in these studies; 
however cancer-specific survival is a key metric for all concerned with providing quality 
oncologic care.
Like hospital procedural volume, CoC accreditation is a measureable hospital characteristic; 
however unlike volume, the relationship between CoC accreditation and patient outcomes 
has not been well studied. The CoC is a conglomerate of over 50 organizations that focus on 
improving oncologic outcomes and quality of life for cancer patients [10–13]. The CoC 
provides standards, prevention, research, education and quality monitoring and accreditation 
is based on compliance and adherence to these guidelines[10]. CoC accredited hospitals are 
more likely to have oncology-related services including screening programs, chemotherapy, 
radiation, survivorship and hospice services and they are required to report to the National 
Cancer Data Base [11]. CoC accreditation is one method patients can use to assess healthcare 
quality. However, the association between performance on national quality indicators and 
CoC accreditation has not been firmly established [11–13].
In order to provide patients with additional information from which to make informed 
healthcare decisions regarding the quality of oncologic outcomes in NSCLC, we analyzed 
data from the California Cancer Registry (CCR). We hypothesized that increased cancer-
specific survival would be seen in high volume centers and centers with CoC accreditation.
Methods
This was a University of California, Davis Institutional Review Board (IRB)-approved, 
retrospective cross-sectional study of patients diagnosed with NSCLC through the CCR. 
Consent was waived because only de-identified data were included in the study. The CCR, a 
program of the California Department of Public Health, is a population-based registry that 
has collected cancer incidence and mortality data for the entire population of California 
since 1988. By law (Health and Safety Code, Section 103885), all new reportable cancer 
cases diagnosed in California residents must be provided to the CCR, and data are collected 
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from diagnostic and treatment facilities[14]. To ensure current follow up for vital status and 
cause of death, the CCR database is linked annually to death certificates, hospital discharge 
data, Medicare files, the Department of Motor Vehicles, Social Security, and other 
administrative databases. Linkage to the National Death Index ensures capture of deaths 
occurring outside California as well as cause of death, and follow up is over 96% for 
patients diagnosed since 2000. The CCR is a participant in both the Centers for Disease 
Control National Program of Cancer Registries and the National Cancer Institute 
Surveillance Epidemiology and End Results (SEER) program, which requires the highest 
standards of data quality, as judged by completeness, accuracy, and timeliness.
Data extracted from medical records include patient demographics (age, gender, race, 
socioeconomic status), year of diagnosis, tumor characteristics, stage at diagnosis, and 
hospital and physician information. Race/ethnicity in the CCR is based on information 
collected from medical records supplemented with linkage to algorithms to better identify 
Hispanics and Asian/Pacific Islanders. Race/ethnicity was categorized as non-Hispanic 
white, non-Hispanic black, Hispanic, and non-Hispanic Asian/other. Patient address at 
diagnosis is assigned to a census tract, and neighborhood socioeconomic status (SES) was 
based on U.S. Census characteristics combined into the summary Yost index[15], categorized 
as low, medium, and high SES.
Only patients for whom NSCLC was the first or only cancer diagnosis were included. 
Patients diagnosed at autopsy were excluded from analysis. Stage at diagnosis was defined 
based on the SEER modification of the AJCC staging system, and only patients diagnosed as 
Stage I and treated with surgery were included in this analysis. Hospitals where definitive 
surgery was performed were categorized by Commission on Cancer (CoC) accreditation and 
average number of lobectomies or sublobar resections performed during the study period 
(Low < 20, Medium (20–50), High (> 50). Patients treated at major hospitals that had 
previously been CoC accredited were categorized as CoC accredited. Hospitals with invalid 
codes were excluded. Patients were followed through December 31, 2011.
Patient’s demographic information, hospital, and tumor characteristics were summarized 
using descriptive statistics. Two-sided Chi-square tests were used to determine whether 
baseline characteristics were significantly different between the two treatment groups. The 
overall survival was estimated using Kaplan-Meier method within hospital volume 
categories and CoC accreditation. Log-rank tests were conducted to examine whether the 
unadjusted differences in survival between the two groups were statistically significant. 
Multivariable PH Cox regression analysis was performed for the cause-specific survival 
analysis with hospital volumes and CoC accreditation as the main predictors of interest, 
adjusting for patient’s age, gender, race, Socio-economic status (SES), tumor stage, and 
types of treatment. We considered p-values less than 0.05 as statistically significant. All 
statistical analyses were conducted using SAS for Windows, version 9.3 (SAS Institute 
Cary, NC).
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The California Cancer Registry identified 8,345 patients with Stage 1 NSCLC who were 
treated from 2004–2011. Of these, 7,587 were treated with surgical resection consisting of 
either lobectomy or sublobar resection. The patients were a median age of 70, 56% were 
women, and 73% were white (Table 1). Seventy-four percent of patients were treated in a 
CoC accredited facility. Thirty-four percent (2575/7587) of patients were treated in high 
volume centers for lobectomy, 48% (3610/7587) were treated in medium volume centers 
and 18% (1392/7587) were treated in low volume centers. Most patients underwent 
lobectomy (82%) as opposed to sublobar resection (18%). A majority of hospitals were low 
volume and most hospitals were non-teaching, urban, not-for-profit hospitals.
To illustrate the effects of hospital volume and CoC accreditation on cancer-specific 
survival, Kaplan-Meier plots are shown in Figure 1a and b. As shown in Figure 1a, cancer-
specific survival was significantly longer for patients treated in high volume centers (log-
rank test, p<0.0001). Figure 1b demonstrates better cancer-specific survival in hospitals with 
CoC-accreditation (log-rank test, p<.001).
Lobectomy, female gender, high SES, and Stage 1A disease were predictive of increased 
cancer-specific survival after adjustment for other factors. (Table 2) Age >65 was associated 
with decreased cancer-specific survival. Hispanic and Asian/Pacific Islanders demonstrated 
longer cancer-specific survival when compared to Non-Hispanic whites. There was no 
statistical difference between cancer-specific survival for Caucasians and African-
Americans. Treatment in a high volume center was associated with longer cancer-specific 
survival when compared to low and medium volume centers. CoC accreditation was not a 
significant predictor of cancer-specific survival. When the analysis was confined to patients 
treated in low volume hospitals, CoC accreditation continued to have a non-significant effect 
on survival (HR=1.201, CI=0.930–1.552).
Comment
When facing a diagnosis of early-stage NSCLC, patients must make an educated decision 
about where to obtain treatment. To make these decisions, they must weigh perioperative 
outcomes and long-term oncologic outcomes. However, patients commonly rely on hospital 
characteristics and other third party designations as surrogate markers for outcomes and 
quality of care in order to inform their medical decision-making. Many studies have focused 
on the relationships between hospital volume and perioperative outcomes, but few have 
found that hospital volume impacts long-term cancer specific survival [16]. Our data are 
novel by demonstrating increased cancer-specific survival for early-stage NSCLC patients 
treated surgically in high volume centers. Although some have suggested that the early 
benefits seen by patients in high volume centers do not result in long-lasting effects on 
oncologic outcomes, our data suggest otherwise.
In addition to hospital procedural volume, we chose to examine the effect of CoC 
accreditation, another hospital characteristic, on cancer-specific survival. The Commission 
on Cancer is a program of the American College of Surgeons, established for the purpose of 
recognizing cancer programs for providing high-quality cancer care. Knutson et al, 
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demonstrate the value that physicians and administrators place on CoC accreditation, with 
over 90% of respondents agreeing that accreditation improves patient care and outcomes[12]. 
However, data are not clear regarding the correlation between accreditation status and 
outcomes. Merkow et al demonstrated that CoC accredited facilities were likely to perform 
less well than non-accredited centers on venous thromboembolism prophylaxis, serious 
complication composite scores, catheter-associated bloodstream and urinary tract infection, 
as well as glycemic control[13]. In our series, we did not observe an independent effect of 
CoC accreditation on cancer-specific survival; and on subset analysis of low volume 
hospitals, we did not observe a significant effect of CoC accreditation on survival. Therefore 
these data suggest that CoC accreditation may reflect the ability of a facility to adhere to 
guidelines and standards, rather than its clinical outcomes; and that outcomes from thoracic 
surgery are related more strongly to surgeon and hospital experience.
The search for adequate measures of quality for surgical outcomes is ongoing. Kozower et al 
performed a large analysis of the Society of Thoracic Surgeons (STS) General Thoracic 
Database examining over 18,000 lung cancer resections performed in 111 facilities[17]. 
Significant differences were found between the hospitals that performed the best and worst 
among 30-day outcomes, but the predictors of improved hospital performance were poorly 
understood and long-term outcomes were not measured because of STS database limitations. 
The CCR has limited clinical information and therefore perioperative outcomes are not 
available for analysis, but cancer-specific survival can be examined. The lack of detailed 
clinical data in the CCR makes risk-adjustment impossible in our series. However, there are 
notable strengths to this analysis, including the large number of patients diagnosed with 
Stage 1 NSCLC, the diversity of the patient cohort, and the ability to measure long-term 
cancer specific mortality.
Many series have established a relationship between high surgical volume and improved 
perioperative outcomes across cancer specialties, but the use of hospital volume as a 
measure of quality remains controversial because of lack of consistency in the measurement 
of hospital volume [1, 3–6, 18–20]. Most series, including ours, categorize hospital volume into 
tertiles or quintiles. Kozower et al compared 3 techniques for calculation of hospital volume 
and suggest that the impact of hospital volume is dependent on how volume is defined and 
entered into the regression equation[21]. Despite these findings, the analysis of hospital 
volume as a nonlinear function using restricted cubic splines has not been widely adopted.
Conclusion
In the era of transparency of outcomes and public reporting, these reported outcomes are 
challenging for patients and physicians to interpret. Hospital volume should not be viewed 
as the sole determinant of quality, but it should be recognized as an important and 
significant factor contributing to decreased perioperative morbidity and mortality as well as 
increased cancer-specific survival. CoC accreditation may reflect a measure of adherence to 
standards and processes of care, but the lack of correlation with oncologic outcomes in this 
series is notable and warrants further investigation.
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Figure 1. Kaplan-Meier Cancer Specific Survival Curves
A. Hospital Volume, (log-rank test, p<0.0001) B. CoC Accreditation (log-rank test, p<.001)
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 <50 231 3.0
 50–64 1934 25.5
 >65 5422 71.5
Sex
 Male 3359 44.3
 Female 4228 55.7
Race
 Non-Hispanic, White 5585 73.6
 Non-Hispanic, Black 441 5.8
 Hispanic 646 8.5
 Asian/Pacific Islander 870 11.5
 Other 45 0.6
SES
 Lowest/lower-middle 2365 31.1
 Middle 1668 22.0
 Higher-middle/Highest 3287 43.3
 Unknown 267 3.5
Stage of disease
 Stage 1A 4682 61.7
 Stage 1B 2905 38.3
Surgery in a CoC accredited Hospital
 Yes 5620 74.1
 No 1967 26.0
Hospital Volume
 Low <20 1392 18.3
 Medium 20–50 3610 47.6
 High >50 2575 33.9
 Unknown 10 0.1
Type of Surgery
 Sublobar resection 1363 17.9
 Lobectomy 6224 82.0
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 50–64 1.025 (0.652, 1.610)
 65+ 1.616 (1.046, 2.496)
Sex
 Male 1.237 (1.091, 1.041)
 Female Reference
Race
 Non-Hispanic White Reference
 Non-Hispanic Black 0.908 (0.695, 1.186)
 Hispanic 0.743 (0.580, 0.951)
 Asian/Pacific Islander 0.706 (0.0.567, 0.879)
SES
 Low SES 1.239 (1.069, 1.436)
 Medium SES 1.141 (0.972, 1.340)
 High SES Reference
SEER stage
 IA Reference
 IB 1.895 (1.670, 2.150)
CoC accreditation
 Yes Reference
 No 1.047 (0.904, 1.213)
Hospital volume
 Low (<20) 1.777 (1.474, 2.141)
 Medium (20–50) 1.234 (1.058, 1.438)
 High (>50) Reference
Treatment
 Lobar resection 0.614 (0.528, 0.713)
 Sublobar resection Reference
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